MREO
Mereo BioPharma Group plcHealthcare·Biotechnology
$0.34
$55M market cap
Revenue
$0.0M
Free Cash Flow
$-12.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late l
2-Year Price History
$0.28-91.8%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -8.5 | -8.8 | -6.7 | -4.3 | -4.3 | -0.0 | 36.2 | 0.0 | 160.4 | -555.9% | -422.3x | -- |
| Act | 2025-Q4 | 0.0 | -6.7 | -8.4 | -7.4 | -7.7 | -7.7 | -0.0 | 41.0 | 0.2 | 159.4 | -248.7% | -292.9x | -- |
Valuation & Metrics
Market Stats
Price$0.34
Market Cap$55M
Enterprise Value$19M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-21.8%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-14.1M
Free Cash Flow$-12.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-402.3%
WC Change % Rev0.0%
Interest Coverage-5060.9x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares6.5M
Days to Cover4.4
Change (vs Prior)-21.3%
Need at least 2 settlement dates for chart
Employees
Headcount36
Revenue / Employee$0
Gross Profit / Employee$-8,458
Cash Runway
36.2months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
56.1%(-513.5% YoY)
54 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.4%(-1.7% YoY)
3 filers
Vanguard, iShares, SPDR
Market makers
0.5%(-1.3% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Rubric Capital Management LP | $5.1M | $2.15 | +$0 | +$0 | +0.4% | $8.16B |
| EcoR1 Capital, LLC | $4.4M | $0.38 | +$1.8M | +$4.4M | -4.8% | $2.34B |
| 683 Capital Management, LLC | $4.0M | $0.75 | −$998K | +$2.4M | -2.1% | $1.02B |
| BANK OF AMERICA CORP /DE/ | $2.7M | $0.51 | +$2.7M | +$2.6M | -0.1% | $1.36T |
| Defilade Capital Management, L.P. | $2.5M | $0.33 | +$2.5M | +$2.5M | +2.1% | $680M |
| Newtyn Management, LLC | $2.3M | $0.33 | +$2.3M | +$2.3M | -4.1% | $936M |
| MILLENNIUM MANAGEMENT LLC | $1.2M | $1.92 | +$1.1M | +$1.0M | -0.5% | $127.40B |
| Tejara Capital Ltd | $672K | $1.32 | −$40K | −$160K | -1.8% | $303M |
| UBS Group AG | $492K | $2.73 | −$23K | +$184K | -0.3% | $562.11B |
| Wealthspire Advisors, LLC | $263K | $0.33 | +$262K | +$263K | -0.3% | $12.72B |
| MARSHALL WACE, LLP | $227K | $3.60 | −$27K | −$27K | +0.6% | $92.71B |
| GROUP ONE TRADING LLCMM | $111K | $1.08 | −$35K | +$100K | -1.6% | $3.02B |
| Rangeley Capital, LLC | $109K | $0.42 | −$11K | +$109K | -1.2% | $91.1M |
| BlackRock, Inc.Passive | $100K | $3.20 | −$3K | +$9K | -0.2% | $5.69T |
| Knott David M Jr | $99K | $3.72 | +$0 | −$6K | -0.2% | $168M |
| ACADIAN ASSET MANAGEMENT LLC | $68K | $1.09 | +$49K | +$68K | -0.5% | $70.48B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $65K | $3.01 | −$98K | +$7K | -0.6% | $77.14B |
| TWO SIGMA INVESTMENTS, LP | $62K | $2.23 | −$111K | −$19K | -0.9% | $117.03B |
| ADAR1 Capital Management, LLC | $50K | $1.32 | +$0 | +$46K | +8.3% | $1.64B |
| JANE STREET GROUP, LLCMM | $46K | $2.37 | −$71K | −$2K | -0.1% | $92.10B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
-1.42%
avg per quarter
Holders (ex-self)
-1.40%
excl. this stock
Buyers (this Q)
-1.06%
20 buyers · $0.01B in
Sellers (this Q)
-1.09%
19 sellers · $0.01B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+3.3%
how holders react when this stock falls
On quiet Qs
-4.6%
−10% to +10% baseline
On rallies (+10%+)
+5.4%
how they react when this stock rises
Holders' portfolio flow this Q
+2.1%
inflows — adds are organic
Sellers' portfolio flow this Q
+6.1%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.4%
Holder mid (any stock)
-3.3%
Holder rally (any stock)
-7.8%
Biggest decreases this quarter
Schonfeld Strategic Advisors LLCexited−$2.5M683 Capital Management, LLC−$998Kα-2.1Logos Global Management LPexited−$771KUBS ASSET MANAGEMENT AMERICAS INCexited−$735KMonaco Asset Management SAMexited−$661KBALYASNY ASSET MANAGEMENT LLCexited−$533KSIMPLEX TRADING, LLCexited−$175KEntryPoint Capital, LLCexited−$167KLUMINUS MANAGEMENT LLCexited−$165KTWO SIGMA INVESTMENTS, LP−$111Kα-0.9
New buyers this quarter
Top-5 holders · 74.9%
Rubric Capital Management LP--
EcoR1 Capital, LLC--
683 Capital Management, LLC--
BANK OF AMERICA CORP /DE/--
Defilade Capital Management, L.P.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Rubric Capital Management LP15.3MJANUS HENDERSON GROUP PLC—ORBIMED ADVISORS LLC—ADAGE CAPITAL PARTNERS GP, L.L.C.—Rock Springs Capital Management LP—MANGROVE PARTNERS—Point72 Asset Management, L.P.—DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)—SUVRETTA CAPITAL MANAGEMENT, LLC—Frazier Life Sciences Management, L.P.—
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (5 analysts)$2.7068490.0%
Current Price$0.34
Analyst Ratings
5
3
Buy: 5Hold: 3Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
49.1%retail-6.9pp
13.0%dark+0.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
MEREO BIOPHARMA: Aggressive Liability Suppression and Significant Dilution Overhang
Overall Risk
7/10
Fraud
4/10
Dilution
9/10
Insolvency
7/10
Earnings Overstated
3/10
Hidden Liabilities
8/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
5/10
Contextually Acceptable
5/10